Drug controller approves commercial launch of low cost Covid test “Feluda”
PTI, Sep 20, 2020, 12:45 PM IST
New Delhi: The Drugs Controller General of India has approved the commercial launch of “Feluda”, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.
This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.
The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use.
CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).
“The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the statement said.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19, it said.
Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.
“The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a “Made in India” product that is safe, reliable, affordable and accessible,” the statement added.
Commenting on the development, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd said, “The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic.
“The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India’s contributions to the global healthcare and scientific research world,” he said.
PromotedListen to the latest songs, only on JioSaavn.com
Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.
He emphasised that this shows the interconnectedness of scientific knowledge and technology and the innovation of the young research team led by Debojyoti Chakraborty and Souvik Maiti.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Epigamia founder Rohan Mirchandani dies of cardiac arrest at age 42
Turned dreams of people into source of income: Priyanka slams govt over GST on exam forms
Goa-bound Vande Bharat train deviates from regular route due to technical snag at Diva station
Mayawati slams BJP, Cong over Ambedkar row
Delhi polls: BJP issues ‘chargesheet’ against Kejriwal; vows to remove AAP from power
MUST WATCH
Latest Additions
Epigamia founder Rohan Mirchandani dies of cardiac arrest at age 42
Turned dreams of people into source of income: Priyanka slams govt over GST on exam forms
Goa-bound Vande Bharat train deviates from regular route due to technical snag at Diva station
Case registered against unknown persons who attempted to attack BJP MLC Ravi
Mayawati slams BJP, Cong over Ambedkar row
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.